These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9714169)

  • 1. Depot medroxyprogesterone acetate (Depo-Provera) and levonorgestrel (Norplant) use in adolescents among clinicians in Northern Europe and the United States.
    Cromer BA; Berg-Kelly KS; Van Groningen JP; Seimer BS; Ruusuvaara L
    J Adolesc Health; 1998 Aug; 23(2):74-80. PubMed ID: 9714169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
    Polaneczky M; Liblanc M
    J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
    Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z
    J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception.
    Cromer BA; Smith RD; Blair JM; Dwyer J; Brown RT
    Pediatrics; 1994 Nov; 94(5):687-94. PubMed ID: 7936897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives.
    Moore LL; Valuck R; McDougall C; Fink W
    Contraception; 1995 Oct; 52(4):215-9. PubMed ID: 8605778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant.
    Harel Z; Biro FM; Kollar LM; Rauh JL
    J Adolesc Health; 1996 Aug; 19(2):118-23. PubMed ID: 8863083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adolescent satisfaction with postpartum contraception and body weight concerns.
    Hellerstedt WL; Story M
    J Adolesc Health; 1998 Jun; 22(6):446-52. PubMed ID: 9627814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of depo-provera in teens.
    Khoiny FE
    J Pediatr Health Care; 1996; 10(5):195-201. PubMed ID: 8920351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug regulation in the United States and the United Kingdom: the Depo-Provera story.
    Richard BW; Lasagna L
    Ann Intern Med; 1987 Jun; 106(6):886-91. PubMed ID: 2953290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women.
    Naessen T; Olsson SE; Gudmundson J
    Contraception; 1995 Jul; 52(1):35-9. PubMed ID: 8521712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of continuation rates for hormonal contraception among adolescents.
    Zibners A; Cromer BA; Hayes J
    J Pediatr Adolesc Gynecol; 1999 May; 12(2):90-4. PubMed ID: 10326194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depo-Provera and Norplant implants prove no competition for no. 1 choice, OCs. The 1994 pill survey.
    American Health Consultants
    Contracept Technol Update; 1994 Dec; 15(12):157-61. PubMed ID: 12288903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting hormonal contraception: assessing impact on bone density, weight, and mood.
    Kaunitz AM
    Int J Fertil Womens Med; 1999; 44(2):110-7. PubMed ID: 10338269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for the use of progestin-only contraceptives.
    Freeman S; Shulman LP
    J Am Acad Nurse Pract; 2010 Feb; 22(2):81-91. PubMed ID: 20132366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of depot medroxyprogesterone acetate contraception in adolescents.
    Davis AJ
    J Reprod Med; 1996 May; 41(5 Suppl):407-13. PubMed ID: 8725703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders.
    Keder LM; Rulin MC; Gruss J
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):583-5. PubMed ID: 9757955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.